Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease

Published:2015-12 Issue:12 Volume:122 Page:2423-2431
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Tauber Joseph,Karpecki Paul,Latkany Robert,Luchs Jodi,Martel Joseph,Sall Kenneth^ORCID,Raychaudhuri Aparna,Smith Valerie,Semba Charles P.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference16 articles.

1. American Academy of Ophthalmology Cornea/External Disease Preferred Practice Panel. 2011. Dry eye syndrome. Limited revision. Available at: http://www.guideline.gov/content.aspx?id=36094. Accessed April 27, 2015.

2. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118);Sun;J Ocul Pharmacol Ther,2013

3. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs;Murphy;Invest Ophthalmol Vis Sci,2011

4. Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye;Zhong;ACS Med Chem Lett,2012

5. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study;Sheppard;Ophthalmology,2014

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease Associated With Ocular Graft-Versus-Host Disease;Cureus;2024-08-08

2. Silk-Derived Protein-4 versus vehicle control in treating patients with moderate to severe dry eye disease: a randomized clinical trial;American Journal of Ophthalmology;2024-08

3. Patented Formulations, Nanotherapeutics and Herbal Compound Applications for Dry Eye: A Review;Current Drug Therapy;2024-06

4. A specific chiral HPLC method for lifitegrast and determination of enantiomeric impurity in drug substance, ophthalmic product and stressed samples;Journal of Pharmaceutical and Biomedical Analysis;2024-05

5. Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease;Drugs;2024-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3